LON:DEST

Destiny Pharma (DEST) Share Forecast, Price & News

GBX 45.50

0.00 (0.00%)

(As of 05/20/2022 12:00 AM ET)

Add

Compare

Today's Range: 45.50
▼
46.20
50-Day Range: 41
▼
52
52-Week Range: 40
▼
162.20

Volume: 70 shs
Average Volume: 40,404 shs
Market Capitalization: £33.35 million

P/E Ratio: N/A
Dividend Yield: N/A
Beta: N/A

30 days | 90 days | 365 days | Advanced Chart

Receive DEST News and Ratings via Email

Sign-up to receive the latest news and ratings for Destiny Pharma and its competitors with MarketBeat's FREE daily newsletter.

About Destiny Pharma

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing NTCD-M3 that is in phase III clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal that is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal, which is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Biofilm for the treatment of of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF Drugs for the treatment of respiratory, oral mucosa, and ocular infection diseases. Destiny Pharma plc has collaboration agreement with China Medical System Holdings Limited; research collaboration with the University of Southampton for targeting infections in diabetic foot ulcers and cystic fibrosis; research collaboration with the University of Sheffield; research collaboration with Aston University to investigate novel compounds from its XF-drug platform; collaboration with Cardiff University and Tianjin Medical University; and Collaboration with SporeGen Limited to co-develop treatment for COVID-19. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.

May 12, 2022 | lse.co.uk

TRADING UPDATES: Belluscura to raise GBP5 million; React buys

May 3, 2022 | lse.co.uk

Destiny Pharma appoints Yuri Martina as chief medical officer

April 29, 2022 | finance.yahoo.com

Pharma Stock Roundup: Q1 Earnings of LLY, MRK & NVS, FDA Updates for AZN & PFE

April 29, 2022 | msn.com

Netflix’s ‘Ozark’ Concludes in Fitting—Yet Shocking—Fashion

April 25, 2022 | apnews.com

Poxel Announces Its Participation in Upcoming Scientific Conferences

April 12, 2022 | proactiveinvestors.com.au

Destiny Pharma undervalued compared to peers, suggests finnCap

March 25, 2022 | nytimes.com

This Economist Really Loves Free Markets

March 25, 2022 | proactiveinvestors.com

Destiny Pharma raises £6.45mln for pipeline development

March 22, 2022 | finanznachrichten.de

POXEL SA: Poxel Reports Financial Results for Full Year 2021 and Provides Corporate Update

March 10, 2022 | uk.investing.com

Destiny Pharma PLC (DEST)

March 8, 2022 | lse.co.uk

Norway-Poland gas pipeline to be ready in Oct-Nov, Polish PM says

March 8, 2022 | marketwatch.com

Destiny Pharma Shares Fall on Discounted Fundraising for Up to GBP7 Mln

February 8, 2022 | lse.co.uk

Destiny upbeat on nasal gel feedback from EMA

See More Headlines

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:DEST
Previous Symbol
CUSIP: N/A
CIK: N/A
Web: www.destinypharma.com
Phone: +44-1273-704440
Fax: N/A
Employees: 14
Year Founded: N/A

Sales & Book Value

Annual Sales: £135.03 thousand
Price / Sales: 247.02
Cash Flow: GBX 7.55 per share
Price / Cash Flow: 6.03
Book Value: GBX 12.50 per share
Price / Book: 3.64

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.74
Quick Ratio: 7.29

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: 73,307,000
Free Float: N/A
Market Cap: £33.35 million
Optionable: Optionable

Company Calendar

Last Earnings: 9/17/2020
Today: 5/22/2022

MarketRank^™

Overall MarketRank^™

0.88 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Destiny Pharma.

4.4 Community Rank

Outperform Votes
Destiny Pharma has received 75 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Destiny Pharma has received 39 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Destiny Pharma has received 65.79% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Destiny Pharma and other stocks. Vote “Outperform” if you believe DEST will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DEST will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Destiny Pharma does not currently pay a dividend.
Dividend Growth
Destiny Pharma does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Destiny Pharma insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Destiny Pharma is -5.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Destiny Pharma is -5.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Destiny Pharma has a P/B Ratio of 3.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Destiny Pharma (LON:DEST) Frequently Asked Questions

How were Destiny Pharma's earnings last quarter?: Destiny Pharma plc (LON:DEST) released its quarterly earnings results on Thursday, September, 17th. The company reported ($5.50) earnings per share for the quarter.
View Destiny Pharma's earnings history.
Who are Destiny Pharma's key executives?: Destiny Pharma's management team includes the following people:
Mr. Neil Robert Clark, CEO & Director (Age 59, Pay $325k)
Dr. William Guy Love, Founder, Chief Scientific Officer & Director (Age 59, Pay $275k)
Mr. Shaun Claydon ACA, CFO, Company Sec. & Director (Age 53, Pay $240k)
Dr. Jesús M González Moreno, Chief Medical Officer
Dr. Stephanie Bewick, Chief Bus. Officer
Who are some of Destiny Pharma's key competitors?: Some companies that are related to Destiny Pharma include Aptose Biosciences (APS), Faron Pharmaceuticals Oy (FARN), Tiziana Life Sciences (TILS), Novacyt (NCYT), Verseon (VSN), IMV (IMV), Arecor Therapeutics (AREC), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Scancell (SCLP), e-therapeutics (ETX), Novoheart (NVH), Open Orphan (ORPH), Mereo BioPharma Group plc (MPH.L) (MPH) and Burcon NutraScience (BU).
View all of DEST's competitors.
What other stocks do shareholders of Destiny Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Destiny Pharma investors own include Dynavax Technologies (DVAX), AFPO.L (AFPO), Aldeyra Therapeutics (ALDX), Ares Capital (ARCC), BioCryst Pharmaceuticals (BCRX), BioNTech (BNTX), Centamin (CEY), Countryside Partnerships (CSP), Enbridge (ENB) and EQTEC (EQT).
What is Destiny Pharma's stock symbol?: Destiny Pharma trades on the London Stock Exchange (LON) under the ticker symbol "DEST."
How do I buy shares of Destiny Pharma?: Shares of DEST and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is Destiny Pharma's stock price today?: One share of DEST stock can currently be purchased for approximately GBX 45.50.
How much money does Destiny Pharma make?: Destiny Pharma has a market capitalization of £33.35 million and generates £135.03 thousand in revenue each year.
How many employees does Destiny Pharma have?: Destiny Pharma employs 14 workers across the globe.
What is Destiny Pharma's official website?: The official website for Destiny Pharma is www.destinypharma.com.
How can I contact Destiny Pharma?: Destiny Pharma's mailing address is Sussex Innovation Centre Science Park Square, Falmer, BRIGHTON, BN1 9SB, United Kingdom. The company can be reached via phone at +44-1273-704440.

This page was last updated on 5/22/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Your Ultimate Investing Toolkit

Just $1.00 for your first month.